Diana Lemaire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diana Lemaire has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Pollett
Mount Sinai Hospital, Toronto, ON, Canada
2 shared publications - Alan Spatz
Department of Pathology, McGill University and Department of Pathology, Jewish General Hospital, and Lady Davids Institute for Medical Research, Montreal, QC, Canada
2 shared publications - Bryan Lo
Ottawa Hospital Research Institute, Ottawa, ON K1R 6M1, Canada
2 shared publications - Christine Williams
Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON K7L 3N6, Canada
2 shared publications - Don Husereau
School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada
2 shared publications - Erik Nohr
Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary, AB, Canada
2 shared publications
Latest Publications
- Open Access
- 31 October 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (11) , 9660-9669
Future Role of Health Technology Assessment for Genomic Medicine in Oncology: A Canadian Laboratory Perspective
Genome-based testing in oncology is a rapidly expanding area of health care that is the basis of the emerging area of precision medicine. The efficient and considered adoption of novel genomic medicine testing is hampered in Canada by the fragmented nature of health care oversight as well as by lack of clear and transparent processes to support rapid evaluation, assessment, and implementation of genomic tests. This article provides an overview of some key barriers and proposes approaches to addressing these challenges as a potential pathway to developing a national approach to genomic medicine in oncology.
- 31 October 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (11) , 9660-9669
Open AccessFuture Role of Health Technology Assessment for Genomic Medicine in Oncology: A Canadian Laboratory Perspective
Genome-based testing in oncology is a rapidly expanding area of health care that is the basis of the emerging area of precision medicine. The efficient and considered adoption of novel genomic medicine testing is hampered in Canada by the fragmented nature of health care oversight as well as by lack of clear and transparent processes to support rapid evaluation, assessment, and implementation of genomic tests. This article provides an overview of some key barriers and proposes approaches to addressing these challenges as a potential pathway to developing a national approach to genomic medicine in oncology.
- Open Access
- 17 August 2023
- Published by MDPI AG in Preprints.org
Future role of Health Technology Assessment for Genomic Medicine in Oncology: A Canadian Laboratory Perspective
Genome-based testing in oncology is a rapidly expanding area of health care which is the basis of the emerging area of precision medicine. Efficient and considered adoption of novel genomic medicine testing is hampered in Canada by the fragmented nature of health care oversight as well as by lack of clear and transparent processes to support rapid evaluation, assessment and implementation of genomic tests. This article provides an overview of some key barriers and proposes approaches to addressing these challenges as a potential pathway to developing a national approach to genomic medicine in oncology.
- 17 August 2023
- Published by MDPI AG in Preprints.org
Open AccessFuture role of Health Technology Assessment for Genomic Medicine in Oncology: A Canadian Laboratory Perspective
Genome-based testing in oncology is a rapidly expanding area of health care which is the basis of the emerging area of precision medicine. Efficient and considered adoption of novel genomic medicine testing is hampered in Canada by the fragmented nature of health care oversight as well as by lack of clear and transparent processes to support rapid evaluation, assessment and implementation of genomic tests. This article provides an overview of some key barriers and proposes approaches to addressing these challenges as a potential pathway to developing a national approach to genomic medicine in oncology.